Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006001 · ClinicalTrials.gov registry record · Phase 2
SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT00006001: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00006001 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006001, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic or locally recurrent colorectal cancer. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor.
Interventions
- DRUG semaxanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2000-08 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006001
The ClinicalTrials.gov registry entry for NCT00006001 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which semaxanib is the first listed.
NCT00006001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006001 about?
NCT00006001 is a clinical study titled "SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer". Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic or locally recurrent colorectal cancer. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor.
What is the current status of trial NCT00006001?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2000-08. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00006001?
The interventions under investigation include: semaxanib (DRUG).
Who is sponsoring clinical trial NCT00006001?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.